Company news

Biomea Fusion, Inc. news in 2026

Biomea Fusion, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Biomea Fusion to Participate in Upcoming Investor Conferences

November 12, 2026

Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights

November 10, 2026

Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026

November 10, 2026

Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist

October 13, 2026

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

October 12, 2026

Biomea Fusion Announces Termination of Proposed Public Offering of Securities

September 23, 2026

Biomea Fusion to Participate in Upcoming Investor Conferences

September 3, 2026

Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

August 24, 2026

Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity

August 13, 2026

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

August 5, 2026

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

June 5, 2026

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

June 3, 2026

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

May 11, 2026

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions

May 5, 2026

Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

April 27, 2026

Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

March 30, 2026

Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights

March 24, 2026

Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026

March 14, 2026

Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones

January 12, 2026

Decks in 2026